Bulk Pharmaceutical API Sources for VASCEPA

Bulk Pharmaceutical API Sources for VASCEPA

Vendor	Vendor Homepage	Vendor Sku	API Url
TCI (Tokyo Chemical Industry)		E0442
Molport		MolPort-006-393-913
Oakwood Products		035939
TCI (Tokyo Chemical Industry)		E0853

Bulk Active Pharmaceutical Ingredient (API) Sources for VASCEPA

Last updated: February 19, 2026

This analysis identifies and evaluates key bulk Active Pharmaceutical Ingredient (API) suppliers for VASCEPA (icosapent ethyl). The market for icosapent ethyl API is characterized by specialized manufacturing requirements due to its high purity standards and therapeutic application. The primary API is derived from highly purified eicosapentaenoic acid (EPA) ethyl ester.

What is the Approved API for VASCEPA?

The approved Active Pharmaceutical Ingredient (API) for VASCEPA is icosapent ethyl, a high-purity ethyl ester of eicosapentaenoic acid (EPA). This specific API is characterized by its purity, with a minimum assay of 96% icosapent ethyl and stringent limits on other omega-3 fatty acid ethyl esters, including docosahexaenoic acid (DHA) ethyl ester. The manufacturing process involves the isolation and purification of EPA from fish oil sources, followed by esterification with ethanol. Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) mandate strict quality control measures to ensure the safety and efficacy of the final drug product.

Who are the Primary Manufacturers of Icosapent Ethyl API?

The manufacturing of icosapent ethyl API is concentrated among a limited number of specialized API producers due to the complex purification and synthesis required. These manufacturers must adhere to stringent Good Manufacturing Practices (GMP) and possess advanced capabilities in handling and processing omega-3 fatty acids.

• AMRI (Albany Molecular Research Inc.): AMRI, now a part of Curia, has been a significant manufacturer of icosapent ethyl API. They operate GMP-compliant facilities and have demonstrated expertise in complex API synthesis and commercial scale production. AMRI's involvement positions them as a critical supplier for the VASCEPA market, supporting its global distribution.

• Chemsrc: While specific details regarding Chemsrc's direct manufacturing of icosapent ethyl API for branded VASCEPA are less publicly documented, they are a prominent supplier of pharmaceutical intermediates and APIs. Their product portfolio often includes complex organic compounds, suggesting potential involvement in the broader omega-3 API supply chain.

• Other Specialized Omega-3 Manufacturers: The market for high-purity omega-3 APIs is served by companies with deep expertise in marine lipid processing. These entities often operate proprietary extraction and purification technologies to achieve the required purity levels of EPA. Identification of all such suppliers can be challenging due to proprietary manufacturing processes and supply agreements. Companies specializing in nutraceutical-grade omega-3s may also have the underlying technology but may not meet the stringent GMP and regulatory requirements for pharmaceutical-grade APIs.

The supply chain for icosapent ethyl API is sensitive to the availability of high-quality marine oil feedstocks and the technological capacity to achieve pharmaceutical-grade purity. Disruptions in these areas can impact global supply.

What are the Key Technical Specifications for Icosapent Ethyl API?

The technical specifications for icosapent ethyl API are critical for ensuring the efficacy and safety of VASCEPA. These specifications are dictated by regulatory filings and pharmacopoeial standards.

• Purity (Assay): The minimum assay for icosapent ethyl is typically 96% [1]. This high purity level is essential to differentiate it from other omega-3 fatty acids and to ensure consistent therapeutic outcomes.

• Impurities: Stringent limits are placed on other omega-3 fatty acid ethyl esters. For instance, docosahexaenoic acid (DHA) ethyl ester is often limited to a maximum of 2.0% [1]. Other related substances, including saturated fatty acids and other unsaturated fatty acids, are also controlled.

• Residual Solvents: Manufacturing processes often involve solvents. Limits for residual solvents, such as ethanol, are defined according to International Council for Harmonisation (ICH) guidelines to ensure patient safety.

• Heavy Metals: The API must comply with pharmacopoeial limits for heavy metals, which are toxic and must be controlled to extremely low levels.

• Water Content: Water content is controlled to ensure API stability and prevent degradation.

• Physical Appearance: The API is typically described as a clear, pale yellow liquid.

• Stability: Icosapent ethyl is susceptible to oxidation. Manufacturers must implement appropriate handling and storage conditions, often including the use of antioxidants and packaging under inert gas, to maintain stability.

These specifications are verified through a battery of analytical tests, including Gas Chromatography (GC) for assay and impurity profiling, Karl Fischer titration for water content, and Inductively Coupled Plasma (ICP) for heavy metals.

What are the Regulatory Hurdles for API Manufacturing?

The manufacturing of icosapent ethyl API faces significant regulatory hurdles to ensure it meets pharmaceutical standards for safety, efficacy, and quality.

• Good Manufacturing Practices (GMP): All manufacturing facilities must comply with current Good Manufacturing Practices (cGMP) as defined by regulatory agencies such as the FDA, EMA, and others. This encompasses rigorous control over all aspects of production, including personnel, facilities, equipment, raw materials, manufacturing processes, packaging, labeling, and quality control. Regular inspections by regulatory bodies are a standard requirement.

• Drug Master Files (DMFs): API manufacturers typically submit Drug Master Files (DMFs) to regulatory agencies. A DMF contains confidential, detailed information about the facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows regulatory agencies to review the API's information without requiring the drug product manufacturer to disclose proprietary details.

• ICH Guidelines: Compliance with International Council for Harmonisation (ICH) guidelines is mandatory. These guidelines cover various aspects of pharmaceutical development and manufacturing, including quality (e.g., Q7 for GMP for APIs, Q3A-D for impurities), safety (e.g., S series), and efficacy (e.g., E series).

• Pharmacopoeial Standards: The API must meet the standards set forth in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). These monographs define specific tests, procedures, and acceptance criteria for the API.

• Supply Chain Integrity: Ensuring the integrity and traceability of the entire supply chain, from raw material sourcing (e.g., fish oil) to the final API, is paramount. This includes controlling potential contaminants, ensuring ethical sourcing, and preventing counterfeiting.

• Process Validation: The manufacturing process must be validated to demonstrate that it consistently produces API meeting predetermined specifications and quality attributes. This involves rigorous testing and documentation.

• Stability Testing: Comprehensive stability studies are required to determine the shelf-life of the API under various storage conditions and to identify potential degradation products.

Adherence to these regulatory requirements is a continuous process, requiring ongoing investment in quality systems, analytical capabilities, and regulatory expertise.

What is the Market Landscape for Icosapent Ethyl API?

The market for icosapent ethyl API is driven by the demand for VASCEPA, a prescription drug used to reduce cardiovascular risk in certain adult patients. The market is characterized by:

• Specialized Niche: The production of high-purity icosapent ethyl API is a specialized niche within the broader API market. It requires expertise in marine lipid chemistry and advanced purification techniques.

• Limited Competition: Due to the technical barriers to entry and stringent regulatory requirements, the number of manufacturers capable of producing pharmaceutical-grade icosapent ethyl API is limited. This can lead to a less competitive landscape compared to generic APIs.

• Supply Chain Vulnerability: The reliance on specific raw material sources (e.g., fish oil) can introduce supply chain vulnerabilities. Factors like environmental conditions, fishing quotas, and global demand for omega-3s can impact feedstock availability and cost.

• Patent Protection: The primary VASCEPA drug product is protected by patents, influencing market dynamics for its API. As patents approach expiration, the market may anticipate the entry of generic competitors, potentially increasing demand for API from alternative suppliers. However, generic approval requires demonstrating bioequivalence and meeting all API specifications, a process that can take time and significant investment.

• Geographic Concentration: API manufacturing expertise in specialized areas can be geographically concentrated. Manufacturers with established capabilities in high-purity omega-3s may be primarily located in regions with advanced chemical manufacturing infrastructure and expertise.

• Quality and Reliability as Differentiators: For drug product manufacturers, the reliability, quality, and regulatory compliance of API suppliers are paramount. Suppliers with a proven track record and robust quality systems command significant trust and business.

The market requires suppliers who can consistently deliver API that meets strict specifications and can scale production to meet global demand. Companies involved in this space must invest heavily in quality assurance, regulatory affairs, and process optimization.

What are the Potential Risks and Opportunities for API Suppliers?

Suppliers of icosapent ethyl API face a unique set of risks and opportunities.

Risks:

• Raw Material Volatility: Fluctuations in the availability and price of high-quality fish oil, the primary feedstock, can significantly impact production costs and margins. Overfishing, environmental concerns, and competition from the nutraceutical sector can affect supply.
• Regulatory Scrutiny: Continuous adherence to evolving GMP standards and stringent regulatory requirements from agencies like the FDA and EMA is essential. Any lapse in compliance can lead to production halts or product recalls.
• Technological Obsolescence: Advancements in purification technologies or the emergence of alternative synthesis routes could render existing manufacturing processes less competitive.
• Competition from Generic Entry: As patents on VASCEPA expire, generic manufacturers may enter the market, potentially leading to price erosion and increased demand for API from multiple, possibly lower-cost, suppliers. This could pressure existing suppliers to optimize costs.
• Supply Chain Disruptions: Geopolitical events, natural disasters, or global health crises can disrupt supply chains, impacting the import/export of raw materials and finished API.

Opportunities:

• Growing Cardiovascular Market: The increasing global prevalence of cardiovascular diseases and the established efficacy of VASCEPA in managing risk factors drive sustained demand for its API.
• Expansion into New Markets: As VASCEPA gains broader regulatory approval and market acceptance in different geographical regions, the demand for its API will expand.
• Process Improvement and Cost Optimization: Manufacturers who can innovate and improve their API production processes to enhance purity, yield, and cost-efficiency can gain a competitive advantage.
• Strategic Partnerships: Forming strong relationships and long-term supply agreements with VASCEPA marketing authorization holders provides revenue stability and predictability.
• Diversification within Omega-3s: Leveraging expertise in high-purity omega-3 manufacturing can open opportunities for supplying other specialty EPA or DHA derivatives for pharmaceutical or high-end nutraceutical applications.
• Vertical Integration: Companies could explore backward integration to secure raw material supply or forward integration into the production of finished dosage forms, though this is a more significant undertaking.

For API suppliers, a robust quality management system, secure feedstock sourcing, continuous process innovation, and strong regulatory compliance are key to navigating risks and capitalizing on opportunities in this specialized market.

Key Takeaways

• Icosapent ethyl, the API for VASCEPA, is a highly purified EPA ethyl ester requiring specialized manufacturing processes.
• Key manufacturers include AMRI (Curia) and potentially other specialized omega-3 producers, with stringent quality and regulatory compliance being paramount.
• Technical specifications demand high purity (>96% icosapent ethyl) and strict control over impurities like DHA ethyl ester.
• Regulatory hurdles are significant, involving cGMP compliance, DMF submissions, adherence to ICH guidelines, and pharmacopoeial standards.
• The market is a specialized niche with limited competition but is subject to raw material volatility and potential generic competition as patents expire.
• API suppliers face risks from raw material fluctuations and regulatory scrutiny but can capitalize on the growing cardiovascular market and opportunities for process optimization.

Frequently Asked Questions

1. What is the primary raw material for icosapent ethyl API? The primary raw material for icosapent ethyl API is fish oil, from which eicosapentaenoic acid (EPA) is isolated and purified.

2. Are there any alternative synthesis routes for icosapent ethyl API? While traditional methods involve isolation and esterification of EPA from natural sources, research into alternative synthesis routes, including biotechnological approaches, is ongoing, though not yet commercially dominant for pharmaceutical-grade API.

3. How does the purity of icosapent ethyl API compare to typical omega-3 dietary supplements? Pharmaceutical-grade icosapent ethyl API has significantly higher purity (typically >96%) and much tighter specifications for impurities compared to omega-3s found in dietary supplements, which often have lower concentrations of individual fatty acids and less rigorous quality control.

4. What is the typical shelf-life of icosapent ethyl API? The shelf-life of icosapent ethyl API is determined by stability studies but is generally extended through careful handling, storage under inert gas, and the addition of antioxidants to prevent oxidation. Specific shelf-lives are documented in the API's regulatory filings.

5. Can any API manufacturer produce icosapent ethyl API, or is specialized expertise required? Specialized expertise in marine lipid chemistry, advanced purification technologies, and strict adherence to pharmaceutical GMP are required. Not all API manufacturers possess the necessary capabilities or regulatory approvals for this specific API.

---

Citations

[1] U.S. Food & Drug Administration. (n.d.). VASCEPA (icosapent ethyl) prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022453s018lbl.pdf